Pelthos Therapeutics (PTHS) Current Deferred Revenue (2025 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Current Deferred Revenue of $966000.0 for Q4 2025, down 5.2% quarter-over-quarter from $1.0 million in Q3 2025.
Pelthos Therapeutics (PTHS) Current Deferred Revenue (2025 - 2026) Analysis & Trends
Pelthos Therapeutics' Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $966000.0 for Q4 2025.
- In Q4 2025, Current Deferred Revenue changed N/A year-over-year to $966000.0; the TTM figure through Dec 2025 stood at $966000.0 (changed N/A YoY), while the FY2025 annual figure was $966000.0, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $966000.0, down from $1.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.0 million in Q3 2025, with the low at $966000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 729,000.00 |
| Dec 31, 2025 | 966,000.00 |
| Sep 30, 2025 | 1.02 Mn |